Table 3a. DFS and OS outcomes for all patients.
5-Year rate |
||||
---|---|---|---|---|
Hazard ratio (95% CI)a | P-valueb | Abbreviated trastuzumab N=115 | Conventional trastuzumab N=112 | |
DFS | 1.31 (0.79–2.12) | 0.31 | 76% | 73% |
OS | 1.37 (0.74–2.54) | 0.32 | 89% | 83% |
Abbreviations: CI=confidence interval; DFS=disease-free survival; OS=overall survival.
Hazard ratio for conventional trastuzumab vs abbreviated trastuzumab.
Based on log-rank test.